RecruitingEarly Phase 1NCT07261306

Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis

Sponsor

Lahore General Hospital

Enrollment

75 participants

Start Date

Aug 29, 2025

Study Type

INTERVENTIONAL

Conditions

Psoriasis

Summary

Psoriasis is a chronic inflammatory dermatoses which include well demarcated scaly erythematous plaques on whole body including scalp role of methotrexate vs tofacitinib is compared in this study

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Inclusion Criteria4

Patients aged 18- 70 years of either gender.
Only patients with Psoriasis Area and Severity Index (PASI) score of 10 or above, and/or Body Surface Area (BSA) involvement of 10% or more, will be included.
Duration of plaque psoriasis for at least 6 months prior to the study.
Psoriasis that has not shown adequate response to topical therapies

Exclusion Criteria5

Individuals with other forms of psoriasis or other significant dermatological conditions that might interfere with the assessment of psoriasis.
Participants currently receiving systemic corticosteroids, biologics, or any other immunosuppressive agents within 4 weeks prior to the start of the study will be excluded.
Known hypersensitivity or contraindications to either methotrexate or tofacitinib.
History of significant liver, kidney, hematologic/bleeding disorder, gastrointestinal/acid peptic disease, or immune system disorders.and any history of tuberculosis and malignancy.
Pregnant or lactating women will not be eligible for the study.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMethotrexate

Methotrexate is an antifolate drug work by inhibiting enzyme dihydrofolate reductase and inhibit cell proliferation and play a role in psoriasis treatment

DRUGTofacitinib

Tofacitinib is janus kinase inhibitor and have role in psoriasis